|
|
???tair.name??? >
???browser.page.title.author???
|
"zhou caicun"???jsp.browse.items-by-author.description???
Showing items 1-8 of 8 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 國立臺灣大學 |
2015 |
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|
Yang, James Chih-Hsin; Wu, Yi-Long; Schuler, Martin; Sebastian, Martin; Popat, Sanjay; Yamamoto, Nobuyuki; Zhou, Caicun; Hu, Cheng-Ping; O'Byrne, Kenneth; Feng, Jifeng; Lu, Shun; Huang, Yunchao; Geater, Sarayut L.; Lee, Kye Young; Tsai, Chun-Ming; Gorbunova, Vera; Hirsh, Vera; Bennouna, Jaafar; Orlov, Sergey; Mok, Tony; Boyer, Michael; Su, Wu-Chou; Lee, Ki Hyeong; Kato, Terufumi; Massey, Dan; Shahidi, Mehdi; Zazulina, Victoria; Sequist, Lecia V.; 楊志新 |
| 國立臺灣大學 |
2015 |
Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis
|
Lee, Chee Khoon; Wu, Yi-Long; Ding, Pei Ni; Lord, Sarah J.; Inoue, Akira; Zhou, Caicun; Mitsudomi, Tetsuya; Rosell, Rafael; Pavlakis, Nick; Links, Matthew; Gebski, Val; Gralla, Richard J.; Yang, James Chih-Hsin; 楊志新 |
| 國立臺灣大學 |
2015 |
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
|
Yang, James C-H; Sequist, Lecia V.; Geater, Sarayut Lucien; Tsai, Chun-Ming; Mok, Tony Shu Kam; Schuler, Martin; Yamamoto, Nobuyuki; Yu, Chong-Jen; Ou, Sai-Hong I.; Zhou, Caicun; Massey, Daniel; Zazulina, Victoria; Wu, Yi-Long; 楊志新; 余忠仁 |
| 國立臺灣大學 |
2015 |
The impact on overall survival (OS) of first-line gefitinib (G) and erlotinib (E) and of clinical factors in advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor mutations (EGFR mut) based on meta-analysis of 1,231 patients (pts) enrolled in 6 major randomized trials.
|
Lee, Chee; Davies, Lucy Claire; Wu, Yi-Long; Mitsudomi, Tetsuya; Inoue, Akira; Rosell, Rafael; Zhou, Caicun; Nakagawa, Kazuhiko; Throngprasert, Sumitra; Fukuoka, Masahiro; Gralla, Richard J.; Gebski, Val; Mok, Tony; Yang, James Chih-Hsin; 楊志新 |
| 國立臺灣大學 |
2013 |
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial
|
Wu, Yi-Long; Lee, Jin Soo; Thongprasert, Sumitra; Yu, Chong-Jen; Zhang, Li; Ladrera, Guia; Srimuninnimit, Vichien; Sriuranpong, Virote; Sandoval-Tan, Jennifer; Zhu, Yunzhong; Liao, Meilin; Zhou, Caicun; Pan, Hongming; Lee, Victor; Chen, Yuh-Min; Sun, Yan; Margono, Benjamin; Fuerte, Fatima; Chang, Gee-Chen; Seetalarom, Kasan; Wang, Jie; Cheng, Ashley; Syahruddin, Elisna; Qian, Xiaoping; Ho, James; Kurnianda, Johan; Liu, Hsingjin Eugene; Jin, Kate; Truman, Matt; Bara, Ilze; Mok, Tony; 余忠仁 |
| 國立成功大學 |
2012-05 |
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
|
Miller, Vincent A.; Hirsh, Vera; Cadranel, Jacques; Chen, Yuh-Min; Park, Keunchil; Kim, Sang-We; Zhou, Caicun; Su, Wu-Chou; Wang, Mengzhao; Sun, Yan; Heo, Dae Seog; Crino, Lucio; Tan, Eng-Huat; Chao, Tsu-Yi; Shahidi, Mehdi; Cong, Xiuyu Julie; Lorence, Robert M.; Yang, James Chih-Hsin |
| 國立臺灣大學 |
2012 |
A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II
|
Mok, Tony; Wu, Yi Long; Thongprasert, Sumitra; Yu, Chong-Jen; Zhang, Li; Ladrera, Guia Elena; Srimuninnimit, Vichien; Sriuranpong, Virote; Sandoval-Tan, Jennifer; Zhu, Yunzhong; Liao, Meilin; Zhou, Caicun; Pan, Hongming; Lee, Victor; Chen, Yuh-Min; Sun, Yan; Margono, Benjamin; Jin, Kate; Truman, Matt; Lee, Jin Soo; 余忠仁 |
| 國立臺灣大學 |
2012 |
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
|
Miller, Vincent A.; Hirsh, Vera; Cadranel, Jacques; Chen, Yuh-Min; Park, Keunchil; Kim, Sang-We; Zhou, Caicun; Su, Wu-Chou; Wang, Mengzhao; Sun, Yan; Heo, Dae Seog; Crino, Lucio; Tan, Eng-Huat; Chao, Tsu-Yi; Shahidi, Mehdi; Cong, Xiuyu Julie; Lorence, Robert M.; Yang, James Chih-Hsin; 楊志新 |
Showing items 1-8 of 8 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
